Buffington Mohr McNeal’s AbbVie ABBV Stock Holding History

Buffington Mohr McNeal’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,680	Closed	-$299K	–	112
2024 Q4	$299K	Hold	1,680	–	–	0.05%	115
2024 Q3	$332K	Hold	1,680	–	–	0.05%	109
2024 Q2	$288K	Buy	1,680 +35	+2%	+$5.8K	0.05%	109
2024 Q1	$300K	Hold	1,645	–	–	0.05%	111
2023 Q4	$255K	Hold	1,645	–	–	0.05%	117
2023 Q3	$245K	Sell	1,645 -263	-14%	-$38.6K	0.06%	113
2023 Q2	$257K	Buy	+1,908	New	+$280K	0.06%	112
2019 Q2	–	Sell	-631	Closed	-$51K	–	118
2019 Q1	$51K	Buy	+631	New	+$51.6K	0.02%	185
2017 Q1	–	Sell	-1,700	Closed	-$106K	–	111
2016 Q4	$106K	Buy	+1,700	New	+$104K	0.04%	166
2016 Q3	–	Sell	-5,200	Closed	-$322K	–	157
2016 Q2	$322K	Sell	5,200 -2,150	-29%	-$131K	0.14%	101
2016 Q1	$419K	Buy	7,350 +1,550	+27%	+$86.4K	0.18%	93
2015 Q4	$344K	Buy	+5,800	New	+$334K	0.18%	76

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Buffington Mohr McNeal's ABBV Position: Q1 2025 in Review

Buffington Mohr McNeal sold out of AbbVie (ABBV) in Q1 2025, closing a stake of 1,680 shares — an estimated $299K sold.

Buffington Mohr McNeal first reported a position in ABBV in Q4 2015 and held it in 12 quarters. The position peaked at $419K in Q1 2016. 3,820 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

Buffington Mohr McNeal reported no remaining AbbVie position as of Q1 2025 after selling out during the quarter.
Buffington Mohr McNeal sold 1,680 AbbVie shares in Q1 2025, an estimated $299K.
Buffington Mohr McNeal first reported a position in AbbVie in Q4 2015 and held it in 12 quarters.
Buffington Mohr McNeal's AbbVie position peaked at $419K in Q1 2016.
3,820 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Buffington Mohr McNeal's 13F filing for Q1 2025, filed 28 Apr 2025.